Metastatic Pancreatic Cancer: Systemic Therapy

@inproceedings{Brown2010MetastaticPC,
  title={Metastatic Pancreatic Cancer: Systemic Therapy},
  author={Jennifer E. Brown and T. R. Jeffry Evans},
  year={2010}
}
Infiltrating ductal adenocarcinoma of the pancreas has an aggressive nature. Approximately 90% of patients have surgically unresectable disease at the time of diagnosis. In addition, the majority of the selected patients who undergo potentially curative resection for small, localised lesions inevitably develop recurrent or metastatic disease. Most systemic therapies have limited efficacy in patients with metastatic disease. Gemcitabine, with or without erlotinib, has modest clinical benefit and… CONTINUE READING